Proteins: emerging carrier for delivery of cancer therapeutics

被引:73
作者
Yewale, Chetan [1 ]
Baradia, Dipesh [1 ]
Vhora, Imran [1 ]
Misra, Ambikanandan [2 ]
机构
[1] Maharaja Sayajirao Univ Baroda, Fac Engn & Technol, Dept Pharm, Vadodara 390001, Gujarat, India
[2] Maharaja Sayajirao Univ Baroda, Fac Engn & Technol, Vadodara 390001, Gujarat, India
关键词
cancer; conjugates; nanoparticles; protein; surface modification; ALBUMIN-BINDING PRODRUG; PROSTATE-SPECIFIC ANTIGEN; IN-VITRO CYTOTOXICITY; PHASE-II TRIAL; SERUM-ALBUMIN; PLASMID DNA; CATIONIZED GELATIN; METHOTREXATE-ALBUMIN; MTX-HSA; TRANSFERRIN CONJUGATE;
D O I
10.1517/17425247.2013.805200
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Over the past decades, proteins have emerged as versatile carriers for the diagnosis and treatment of cancer, diabetes, rheumatoid arthritis, and many more diseases. Proteins have gained considerable attention in formulation of several delivery systems for anticancer drugs due to their nontoxic, non-immunogenic, biocompatible and biodegradable nature. Proteins are good candidates for conjugation with drugs as they provide good pharmacokinetics as well as better cancer tissue accumulation. Protein nanoparticulate systems are also of advancing importance owing to their modifiable functionalities and potential applications in various biological fields. The customizable nature of proteins also makes them outstanding carriers as target-specific delivery systems. Areas covered: This review emphasizes on protein conjugates (drug-albumin, drug-gelatin, drug-transferrin, and drug-antibody conjugates), protein nanoparticles (prepared using albumin, gelatin, casein, silk proteins, elastin, and lectins), surface modification of protein nanoparticles (using surfactant, polyethylene glycol, cationic/thermosensitive polymers, folic acid, monoclonal antibodies, and peptides/proteins), and their preclinical and clinical status with respect to cancer therapy. Expert opinion: The major obstacles for commercial success of protein-based delivery are lack of inexpensive as well as quality methods for their preparation and quality control; and if overcome, proteins will stand out as a superior drug-delivery carrier for cancer therapy.
引用
收藏
页码:1429 / 1448
页数:20
相关论文
共 50 条
  • [41] Cancer targeted therapeutics: From molecules to drug delivery vehicles
    Liu, Daxing
    Auguste, Debra T.
    JOURNAL OF CONTROLLED RELEASE, 2015, 219 : 632 - 643
  • [42] Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
    Han, Geonhee
    Noh, Dahye
    Lee, Hokyung
    Lee, Sangmin
    Kim, Sehoon
    Yoon, Hong Yeol
    Lee, Soo Hyeon
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 199
  • [43] Layer-by-Layer Assembled Antisense DNA Microsponge Particles for Efficient Delivery of Cancer Therapeutics
    Roh, Young Hoon
    Lee, Jong Bum
    Shopsowitz, Kevin E.
    Dreaden, Erik C.
    Morton, Stephen W.
    Poon, Zhiyong
    Hong, Jinkee
    Yamin, Inbar
    Bonner, Daniel K.
    Hammond, Paula T.
    ACS NANO, 2014, 8 (10) : 9767 - 9780
  • [44] Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
    Kunal Nepali
    Jing-Ping Liou
    Journal of Biomedical Science, 28
  • [45] Protein therapeutics as an emerging strategy to deal with skin cancer: A short review
    Kulshrestha, Sunanda
    Goel, Anjana
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (01)
  • [46] Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
    Nepali, Kunal
    Liou, Jing-Ping
    JOURNAL OF BIOMEDICAL SCIENCE, 2021, 28 (01)
  • [47] Nanobiopolymers in cancer therapeutics: advancing targeted drug delivery through sustainable and controlled release mechanisms
    Gulati, Shikha
    Ansari, Nabeela
    Moriya, Yamini
    Joshi, Kumud
    Prasad, Disha
    Sajwan, Gargi
    Shukla, Shefali
    Kumar, Sanjay
    Varma, Rajender S.
    JOURNAL OF MATERIALS CHEMISTRY B, 2024, 12 (46) : 11887 - 11915
  • [48] ROS-induced biodegradable polythioketal nanoparticles for intracellular delivery of anti-cancer therapeutics
    Kim, Jee Seon
    Jo, Sung Duk
    Seah, Geok Leng
    Kim, Insu
    Nam, Yoon Sung
    JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, 2015, 21 : 1137 - 1142
  • [49] Emerging strategies for EphA2 receptor targeting for cancer therapeutics
    Tandon, Manish
    Vemula, Sai Vikram
    Mittal, Suresh K.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (01) : 31 - 51
  • [50] Schlafens: Emerging Proteins in Cancer Cell Biology
    Al-Marsoummi, Sarmad
    Vomhof-DeKrey, Emilie E.
    Basson, Marc D.
    CELLS, 2021, 10 (09)